top of page
All posts.
LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Jul 29, 2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Jun 25, 2025
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Jun 4, 2025
Our Chairman Tony de Fougerolles discusses innate immune rejuvenation
Chairman of LIfT BioSciences, to explore the concept of innate immune rejuvenation – a central pillar of our approach to overcoming...
May 28, 2025
LIfT BioSciences presents preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at American Society of Gene & Cell Therapy 28th Annual Meeting
showcasing its versatility in diseases beyond oncology London, 22 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...
May 22, 2025
LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy
London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
May 19, 2025
Newsletter.
Stay up-to-date with our progress and latest news.
bottom of page